Editor's Corner


If nothing else, PhRMA wins this year's award for chutzpah. Faced with a direct threat of mandated advertising blackouts on new drugs, the trade group counters with a little window dressing that wouldn't satisfy the most mild of reformers in Congress. Their suggestions on how drug companies could voluntarily suppress marketing efforts would appear to be a direct provocation to lawmakers. PhRMA -- and Billy Tauzin -- couldn't have picked a worse time for fumbling the ball.

On a separate note, discerning readers will have noted our new Friday Features. Much as I love to cover biotech, I'm looking for some help: expert columns related to the development of new drugs. If you have anything to submit, please send it my way. Your suggestions would be valued as well. - John Carroll

Suggested Articles

In this week's EuroBiotech Report, AstraZeneca plans 2020 lupus filing, Roche's SMA trial hits endpoint and Kiadis cuts staff in R&D pivot.

In our EuroBiotech roundup this week, NEC and Vaximm ink cancer vaccine pact, Compugen posts cancer data and Lunac raises cash.

Biotech venture fund ATAI Life Sciences has partnered with artificial intelligence drug discovery specialist Cyclica to form a new JV.